Across TCGA pan-cancer cohorts, MYO18A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MYO18A’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where MYO18A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MYO18A is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

LUAD, CCRCC, and HNSC are the cancer types where MYO18A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO18A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	+0.152	<.001	7	view →
CCRCC	Male	All	+0.093	<.001	7	view →
HNSC	Male	All	−0.137	.016	6	view →
LSCC	Male	All	−0.114	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MYO18A RNA expression & survival · all MYO18A data types